[Left ventricular hypertrophy in arterial hypertension].

Area of Science:

• Cardiology
• Hypertension Research
• Cardiac Physiology

Context:

• Arterial hypertension is a prevalent condition frequently complicated by left ventricular hypertrophy (LVH).
• LVH, an increase in cardiac muscle mass, is a physiological response to maintain cardiac output but can lead to detrimental myocardial alterations.
• These alterations include increased collagen, impaired diastolic function, reduced contractility, and coronary perfusion disorders, elevating cardiovascular mortality risk.

Purpose:

• To evaluate the impact of antihypertensive treatments on left ventricular hypertrophy regression.
• To determine the ideal characteristics of antihypertensive drugs considering both blood pressure control and cardiac remodeling.
• To emphasize the importance of simultaneous regression of arterial hypertension and LVH.

Summary:

• Left ventricular hypertrophy is a common early complication of arterial hypertension, characterized by increased myocardial mass and potential adverse alterations.
• While many antihypertensive drugs promote LVH regression, direct vasodilators and diuretics may have inconsistent or detrimental effects.
• The study highlights that antihypertensive agents should not only lower blood pressure but also reduce myocardial mass for optimal cardiovascular protection.

Impact:

• Antihypertensive therapy selection should prioritize drugs that achieve early and sustained regression of left ventricular hypertrophy alongside blood pressure normalization.
• This approach is crucial for mitigating cardiovascular mortality associated with hypertension and LVH.
• Choosing antihypertensive medications with regression capabilities can significantly improve long-term patient prognosis and reduce cardiac remodeling.